IL6R and COVID-19: Anti-IL-6R antibodies such as tocilizumab (NCT04322773) or sarilumab (NCT04359901; NCT04357808), and the anti-IL-6 antibodies clazakizumab (NCT04348500; NCT04381052; NCT04343989; NCT04381052) and olokizumab (NCT04380519) are currently in clinical trials for COVID-19 patients.